Skip to content

PLOS is a non-profit organization on a mission to drive open science forward with measurable, meaningful change in research publishing, policy, and practice.

Building on a strong legacy of pioneering innovation, PLOS continues to be a catalyst, reimagining models to meet open science principles, removing barriers and promoting inclusion in knowledge creation and sharing, and publishing research outputs that enable everyone to learn from, reuse and build upon scientific knowledge.

We believe in a better future where science is open to all, for all.

PLOS BLOGS Speaking of Medicine and Health

This Week in PLOS Medicine: Screening for kidney disease; Xpert MTB/RIF; Ethics of cluster randomized trials

Image Credit: Dj jahir

Four new articles posted this week in PLOS Medicine, focusing on major health burdens and research design:

A systematic review of risk prediction models conducted by Justin Echouffo-Tcheugui and Andre Kengne examines the evidence base for prediction of chronic kidney disease risk and its progression, and the suitability of such models for clinical use.

Maarten Taal discusses the potential benefits, risks, and evidence base related to screening policies for chronic kidney disease, drawing on a new research article in PLOS Medicine.

Nicolas Menzies and colleagues investigate the potential impact and cost-effectiveness of implementing Xpert MTB/RIF for diagnosing tuberculosis in five southern African countries.

The Ottawa Ethics of Cluster Trials Consensus Group sets out 15 recommendations for the ethical design and conduct of cluster randomized trials.

Remember you can comment on, annotate and rate any PLOS Medicine article and see the views, citations and other indications of impact of an article on that articles metrics tab.

Back to top